Our research elucidated that IGF2BP2 could partly recuse the suppressing effect of LINC01133 on ER+ breast cancer, which inferred that IGF2BP2 is also beneficial to the aggressive phenotype of the ER+ breast cancer. This evidence concerns the gene IGF2BP2 and breast carcinoma.